46 eligible overweight women with hypovitaminosis D are assigned to either vitamin D or control group using block randomization method. Vitamin D3 pearl (Zahravi Pharma Co, Tabriz, Iran) containing 50000 IU cholecalciferol or placebo are administered weekly for 12 weeks. Participants in both groups are structured to hold their sun exposure and physical activity habits and not take any vitamin supplements during the study.
For the randomized controlled clinical trial (RCT), the first fifty eligible women were assigned to either the vitamin D or placebo group using the block randomization method. Each Vitamin D3 pearl (Zahravi Pharma Co, Tabriz, Iran) contained 50000 IU cholecalciferol and was administered weekly for 12 weeks according to guidelines for treating vitamin D deficiency. Placebo pearls (Zahravi Pharma Co, Tabriz, Iran) had the identical appearance, taste, and smell as the vitamin D pearls and could only be identified by the package code. The placebo pearls were administered similarly. To keep the study double-blinded, an assistant who was not involved in assessments managed the randomization and supplement assignment procedure. Participants were structured to hold their sun exposure and physical activity habits and not take any vitamin supplements during the study. They were also asked to inform the researcher before taking any new medications. All participants were provided with a moderately reduced diet (a reduction of 300 kcal per day) based on their basal weight. The nutrigenetic study investigated 75 eligible women (including the vitamin D group and the last fifty women who entered the study). The nutrigenetic study protocol was the same as that mentioned above for the vitamin D group in the RCT. Compliance was ensured by weekly text messages and voice calls to remind the users of the supplement on the given day. In addition, the supplement and placebo pearls were presented in two visits; once at the baseline visit and then after six weeks. Pearls packs were collected from each subject (at week 6 and week 12) to check if all the pearls were consumed as recommended. During the first and last visits, anthropometric and laboratory assessments were performed for all subjects. The primary outcomes are improving anthropometric, inflammatory, and metabolic markers of overweight women with hypovitaminosis D.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
46
The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.
Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute (NNFTRI) and Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Tehran, Iran
Serum 25(OH)D
Fasting serum 25-hydroxyvitamin D level
Time frame: 12 weeks
Weight
Subject's weight wearing light clothing
Time frame: 12 weeks
Waist circumference
the measurement at the midpoint between the lowest rib and the iliac crest
Time frame: 12 weeks
Fat mass
Total body fat mass measured by Bioelectrical Impedance analysis method
Time frame: 12 weeks
Serum Fasting Glucose
Fasting serum glucose level
Time frame: 12 weeks
Serum total cholesterol
Fasting serum total cholesterol level
Time frame: 12 weeks
Serum triglyceride
Fasting serum triglyceride level Fasting serum triglyceride leve
Time frame: 12 weeks
Serum hsCRP
Fasting serum high sensitivity c-reactive protein level
Time frame: 12 weeks
Serum IL-6
Fasting serum Interleukin-6 level
Time frame: 12 weeks
Serum TNF-a
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Fasting serum tumor necrosis factor alpha level
Time frame: 12 weeks
Serum PTH
Fasting serum parathyroid hormone level
Time frame: 12 weeks